IRVINE, Calif.--(BUSINESS WIRE)--Ivantis, Inc., developer of the novel Hydrus™ Microstent, an investigational device designed to lower eye pressure in patients with open angle glaucoma, today ...

The Hydrus microstent used in conjunction with cataract surgery achieves significant and sustained lowering of intraocular ... FDA Clears Hydrus Microstent for Glaucoma - Medscape - Aug 14, 2018 ...

AAO: Microstent Cuts Intraocular Pressure in Glaucoma For patients with mild-to-moderate open-angle glaucoma, implantation of a nickel titanium microstent (Hydrus Microstent) is associated with ...

In the 40 patients having Hydrus surgery alone, mean IOP was 21.6 mm Hg at baseline and dropped to 17.9 mm Hg 12 months after device implantation (P < .05).Mean number of glaucoma medications was ...

Eyes that were treated with the Hydrus microstent, which is designed to lower eye pressure, were less likely than untreated eyes to need subsequent invasive glaucoma surgery (6.4% vs 2.5%; P=0.022 ...

Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio Expands Alcon’s leading surgical portfolio and leverages the company ...

Interventional glaucoma refers to the mindset that in first-line treatment for this condition, we consider procedural ...

In this exclusive surgical video for Healio, I. Paul Singh, MD, implants the Hydrus microstent from Alcon in a patient with glaucoma following cataract surgery.

Alcon to Acquire Ivantis, Inc. and its Hydrus Microstent for Surgical Glaucoma, Strengthening Global Ophthalmology Portfolio Published. Nov 8, 2021 12:59AM EST.

IRVINE, Calif., Nov. 13, 2017 /PRNewswire/ -- Ivantis Inc., developer of the novel Hydrus® Microstent, a micro-invasive glaucoma surgical (MIGS) device designed to lower eye pressure for open ...

Ivantis reeled in a $25 million Series C rou | Ivantis reeled in a $25 million Series C round to advance the development of its glaucoma-treating microstent through commercialization.